secwatch.observer — SEC 8-K summary
======================================

Issuer:     BICYCLE THERAPEUTICS PLC (BCYC)
CIK:        0001761612
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001104659-22-085864
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicycle Therapeutics reports Q2 net loss $26.8M, cash $372.8M; Genentech expands collaboration
--------------------------------------------------------------------------------

- Net loss $26.8M ($0.90/share) vs $17.9M ($0.74) in Q2 2021, driven by higher R&D and G&A costs.
- Cash $372.8M as of June 30, 2022, down from $438.7M; expected runway into 2025.
- Genentech exercised option to expand immuno-oncology collaboration, triggering $10M payment to Bicycle in Q3 2022.
- BT8009 Phase I interim data: 50% ORR in urothelial cancer at 5.0mg/m2 weekly; four of five responders on therapy >24 weeks.
- Expansion cohorts of BT5528 Phase I/II trial initiated; BT7480 Phase I/II poster presented at ASCO 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761612/000110465922085864/0001104659-22-085864-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761612/000110465922085864/tm2222487d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-085864

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer